Antibody-Drug Conjugates: Carbon-14 Labeling Requirements

The next blockbuster drug revenue streams are likely to come from a class of targeted therapies geared towards the treatment and management of chronic human disease states—especially cancer—and involve the use of antibody-drug conjugates (ADCs).1 A wide range of monoclonal antibodies (mAb) have already been approved by the FDA and includes six engineered monoclonal antibodies Rituxan (rituximab), Herceptin (trastuzumab), Campath (alemtuzumab), Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab). Two radionuclideconjugated monoclonal antibodies Zevalin (ibritumomab tiuxetan) and Bexxar (tositumomab; iodine-131 tositumomab) have also been approved by the FDA.2